Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV in the United States. People with HIV are up to 17 times more likely to get NHL than people who do not have HIV. The disease may also be different in these two groups. More study is needed for treating people with both HIV and NHL. Objective: To test a study drug (pomalidomide) in combination with chemotherapy with or without another drug (rituximab) in people with HIV-associated NHL. Eligibility: Adults aged 18 years or older diagnosed with HIV-associated B-cell NHL with high-risk features. Design: Individuals will undergo screening. They will have a physical exam. They will have blood and urine tests and tests of heart function. They may have imaging scans. Researchers will review tissue samples of individual s tumors. In some cases, a new biopsy may be needed. Individuals will receive up to 6 cycles of treatment. The first cycle is 26 days: Individuals will take pomalidomide by mouth for 10 days. After 5 days they will start receiving chemotherapy drugs through a tube attached to a needle placed in a vein (IV). Some participants will receive rituximab on day 5. All individuals will receive a second set of IV drugs that will last for 4 days (96 hours). They will receive another IV drug after the previous treatment is complete. The remaining cycles are each 21 days. Individuals will take pomalidomide by mouth for the first 10 days. Other chemotherapy treatments will also be repeated starting on day 1 of each cycle. Screening tests will be repeated at study visits. Follow-up visits will continue for 4 years....
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby dorosłe (od 18 lat) z HIV i chłoniakiem typu B, który ma cechy wysokiego ryzyka.
- •Chłoniak musi być potwierdzony badaniami laboratoryjnymi.
- •Chłoniak musi być widoczny lub możliwy do oceny.
- •Osoby nie mogą być wcześniej leczone chemioterapią mającą na celu wyleczenie chłoniaka.
- •Kobiety i mężczyźni w wieku rozrodczym muszą stosować skuteczne metody antykoncepcji.
✗ Disqualifies
- •Osoby z problemami neurologicznymi lub płynem w mózgu związanymi z chłoniakiem.
- •Osoby, u których chłoniak może szybko rozprzestrzenić się do mózgu.
- •Osoby z chłoniakiem, którego budowa komórek jest specyficzna (plazmablastyczna).
- •Osoby z guzem zawierającym wirus gamma herpes.
- •Osoby, u których występuje mięsak Kaposiego.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 30, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
Anaida Widell
Ramya M Ramaswami, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.